A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Trial Profile

A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; PGG-glucan (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biothera
  • Most Recent Events

    • 19 Jul 2017 According to a Biothera Pharmaceuticals media release, patient dosing has commenced in this trial.
    • 22 Dec 2016 Status changed from planning to recruiting.
    • 24 Aug 2016 According to a Biothera Pharmaceuticals media release, this trial is likely to initiate in Fall 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top